ClinicalTrials.gg
Not yet recruitingNCT04176081SChLAP/IDCUpdated Jan 24, 2024

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

A Phase 2 interventional study of Darolutamide and Degarelix in Prostate Cancer, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Planned enrollment
15th of 59
208 · median 80
Started
2024
with 6 others
Phase 2
29 of 59
16 open now
Primary completion
2028-12
later than 30 of 39 live
Registered
15th of 59
by date

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 15th largest by planned enrollment, is one of 7 that started in 2024, is one of 29 in phase 2, reaches primary completion later than 30 of the 39 other live ones, and was the 15th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as Intermediate-Risk PCa (IR-PCa).

The standard treatment for IR-PCa is radiation therapy (RT) with or without hormone therapy which can result in cure in some men. In other men, the cancer can come back or spread to other areas of the body. Treatment response in men with IR-PCa is highly variable. This uncertainty has led to significant under- and over-treatment.

This study aims to find out if the addition of intensive treatment (hormonal therapy: darolutamide + degarelix) to standard treatment for PCa will work better than standard treatment alone. To do this, some participants will receive hormone therapy and others will not. All participants will receive RT.

Currently, it is difficult to identify men who may require more intensive therapy. Current methods, such as using prostate specific antigen (PSA) alone, may not give the doctor enough information about who requires more intensive treatment. The researchers conducting this study believe that a particular arrangement of cancer cells [called intraductal carcinoma (IDC)] and the presence of a genetic marker called SChLAP1 can be used to identify people who would benefit from more intensive therapy.

Hormonal therapy such as with drugs called darolutamide (new drug for PCa) and Degarelix, reduce androgens (male hormones, such as testosterone) or block their effect on the cells. PCa cells require androgens to grow and divide, so removal of androgens may be effective in preventing the return of cancer following radiation therapy.

Although darolutamide has been studied in about 1000 men with PCa and seems promising and well tolerated it is considered an experimental drug, therefore it can only be used in a research study such as this one. Degarelix has been approved by Health Canada to treat PCa.

This is a phase 2, open label, randomized, controlled study and will be conducted across sites in Canada. To qualify, men must have IR-PCa and have both SChLAP1 and IDC present or both absent. Participants will be randomized to receive RT with hormone therapy or RT only. The study treatment period is 6 months for the RT + hormone therapy group. RT will take about 1-2 weeks. All participants will be followed for 5 years with multiple visits to assess safety and treatment effects.

03

Conditions studied

  • Prostate Cancer

Keywords

  • Intraductal carcinoma
  • SChLAP1
  • Radiation therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male ≥ 18 years of age;
  • Pathologic (histologic) proven diagnosis of prostate adenocarcinoma within 180 days prior to consent;
  • PSA measurement performed within 60 days prior to consent;
  • IR-PCa as per National Comprehensive Cancer Network (NCCN) criteria (PSA >10 and \< 20 ng/mL and/or Gleason score 7 and/or T-category T2b-T2c clinical or ultrasound);
  • UIR-PCa, at least one of the following:
  • 2 or 3 NCCN IR-PCa criteria;
  • Gleason score 4+3;
  • >50% diagnostic cores involved by adenocarcinoma;
  • Clinically negative (N0) stage, as defined by pelvic-CT or pelvic-MRI within 4 months prior to consent;
  • No evidence of bone (M0) assessed by a bone scan within 4 months prior to consent;
  • (ECOG) performance status 0-2;
  • Able and willing to provide signed as per International Conference on Harmonization - Good Clinical Practices Guidelines (ICH-GCP) and applicable regulations.

Exclusion criteria

Exclusion Criteria:

  • Received any form of hormonal therapy such as bilateral orchiectomy, LHRH agonist/antagonist (e.g. goserelin, leuprolide, degarelix, etc.), anti-androgens (e.g. flutamide, bicalutamide, etc.), 5α-reductase inhibitors (e.g. finasteride, dutasteride, etc.) and/or estrogens within 1 year of consent;
  • Received prior cytotoxic therapy for prostate cancer (e.g. taxanes, mitoxantrone);
  • Currently taking medications that might cause toxicity if combined with darolutamide (see section 4.6);
  • \< 9.0 g/dL, independent of transfusion and/or growth factors, measured within 90 days prior to consent;
  • count \< 100,000 × 109/μL, independent of transfusion and/or growth factors, within 90 days prior to consent;
  • Serum albumin \< 3.0 g/dL within 90 days prior to consent;
  • Abnormal renal function, assessed within 90 days prior to consent:
  • Creatinine > 2mg/dL;
  • (GFR) ≤ 35 mL/min, estimated by formula or measured directly by 24 hour urine.
  • Abnormal liver function assessed within 90 days prior to consent:
  • Total > 1.5 times the ;
  • Aminotransferases ( or AST) >1.5 times the upper limit of normal range;
  • Currently on anticoagulant therapy for any indication (e.g. atrial fibrillation, valve replacement, pulmonary embolism, etc.);
  • Any cardiac events (e.g. unstable angina, myocardial infarction and/or congestive heart failure;
  • Does not agree to use highly effective method of if he is having sex with a woman of or does not agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 4 weeks following the last dose of study drug;
  • Known (or known allergic reaction) to the study treatment(s) or any of its ingredients (as listed in Investigator's brochure);
  • Planned initiation of alternative therapy for prostate cancer or therapy;
  • Participation in another interventional clinical trial during and / or within 3 months of consent for this study;
  • Subject was previously randomized in this trial;
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (estimated)

Study arms

  • Active comparator
    Group 1: Radiation Therapy Only

    Participants randomized to Group 1 will receive radiation therapy only.

    Radiation: Radiation Therapy

  • Experimental
    Group 2: Radiation Therapy + darolutamide + degarelix

    Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.

    Drug: Darolutamide · Drug: Degarelix · Radiation: Radiation Therapy

Interventions

  • Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.

    Also known as: Nubeqa, ODM-201

  • Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.

    Also known as: Firmagon

  • RadiationRadiation Therapy

    The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).

06

What researchers measure

Primary outcomes

  1. Recurrence Free Survival

    Recurrence Free Survival (RFS), with recurrence event defined as (whichever occurs first): * Biochemical failure defined as per Phoenix criteria (i.e., a rise in PSA by 2 ng/mL or more above the nadir PSA, confirmed by a second PSA measurement) * Clinical, radiographic, or pathological evidence of local, regional, or distant recurrence/metastasis * Initiation of salvage hormonal therapy * Death from any cause.

    Time frame: Recurrence Free Survival will be monitored for a duration of 5 years.

Secondary outcomes

  1. Difference in RFS rates (as defined in primary outcome measure) between IDC/SChLAP1 and treatment groups.

    To prospectively assess the role of IDC/SChLAP1 in UIR-PCa treated with curative intent radiation to predict those who derive the greatest benefit from ST-2gen-ADT.

    Time frame: 5 years

  2. Incidence of early biochemical failure as defined by Pheonix criteria (i.e., within first 2 years of follow-up; surrogate of lethal disease).

    To determine the impact of ADT hormone therapy combined with radiation therapy compared to radiation therapy alone in improving rates of early failures.

    Time frame: 5 years

  3. Rates of positive prostate biopsies (local failure) performed at time of recurrence as per standard of care.

    To assess the patterns of failure after ST-2gen-ADT combined with SABR compared to SABR alone.

    Time frame: 5 years

  4. Testosterone levels

    To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on the duration of castrate testosterone levels (\<50 ng/dL) after treatment completion.

    Time frame: 5 years

  5. Changes in prostate cancer-specific HRQoL as measured by abbreviated EPIC (urinary, bowel, sexual, and hormonal domains) questionnaire, as a function of treatment assignment

    To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on Health Related Quality of Life (HRQOL).

    Time frame: 5 years

  6. Rate of maximal biochemical control, defined as 2 consecutive undetectable PSA (<0.05 ng/mL) during follow-up.

    To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on PSA levels.

    Time frame: 5 years

  7. Rates of positive molecular imaging results (local, regional and/or distant failure) performed at time of recurrence as per standard of care.

    To assess the patterns of failure after ST-2gen-ADT combined with SABR compared to SABR alone.

    Time frame: 5 years

  8. Changes in prostate cancer-specific HRQoL as measured by SF-12 questionnaire, as a function of treatment assignment

    To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on Health Related Quality of Life (HRQOL).

    Time frame: 5 years

Other outcomes

  1. Incidence of treatment-emergent Adverse Events

    To determine the safety of ST-2gen-ADT combined with SABR compared to SABR alone.

    Time frame: 5 years

  2. Tolerability of Treatment

    To determine the tolerability of ST-2gen-ADT combined with SABR compared to SABR alone by determining the number of subjects discontinuing investigational products due to Adverse Events

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Dec 2028, 53 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 53 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2019
First posted
Nov 25, 2019
StartEst.
Jul 2, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04176081
Collaborators
Prostate Cancer Canada, Bayer
Responsible party
Sponsor
First posted
Nov 25, 2019
Start date
Jul 2, 2024 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 24, 2024

Study contacts

Sunakshi Chowdhary
Contact
Sunakshi.Chowdhary@uhn.ca
416-946-4501 ext. 5836
Neil Fleshner, MD
principal investigator · UHN Princess Margaret Cancer Centre
Alejandro Berlin, MD
principal investigator · UHN Princess Margaret Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Degarelix

Start the discussion